✉ Email this page to a colleague
« Back to Dashboard
Amphetamineis the generic ingredient in thirty-one branded drugs marketed by Neos Theraps Inc, Neos Theraps, Actavis Labs Fl Inc, Teva, Takeda Pharms Usa, Actavis Elizabeth, Ani Pharms, Ascent Pharms Inc, Aurolife Pharma Llc, Elite Labs Inc, Granules, Impax Labs, Lannett Co Inc, Nesher Pharms, Par Pharm Inc, Rhodes Pharms, Specgx Llc, Sun Pharm Inds Inc, Sun Pharm Industries, Teva Pharms Usa, Barr Labs Inc, Teva Womens, Accord Hlthcare, Alkem Labs Ltd, Alvogen, Barr, Cediprof Inc, Epic Pharma Llc, Mylan, Nuvo Pharm, Sandoz, Teva Pharms, Uspharma Windlas, Zydus Pharms, Ucb Inc, Azurity, Amneal Pharms, Bionpharma, Cerovene Inc, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Lannett, Novast Labs, Prinston Inc, Rise Pharma, Arbor Pharms Llc, and Tris Pharma Inc, and is included in sixty-nine NDAs. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Amphetamine has two patent family members in two countries.
There are fifty-five drug master file entries for amphetamine. One supplier is listed for this compound.
Summary for amphetamine
|Drug Master File Entries:||55|
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||38|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for amphetamine|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for amphetamine|
|What excipients (inactive ingredients) are in amphetamine?||amphetamine excipients list|
|DailyMed Link:||amphetamine at DailyMed|
Recent Clinical Trials for amphetamine
Identify potential brand extensions & 505(b)(2) entrants
|Stephen Robert Marder||Phase 2|
|Virginia Commonwealth University||Phase 2|
|Boston Children's Hospital||Phase 1|
Pharmacology for amphetamine
|Drug Class||Central Nervous System Stimulant|
|Physiological Effect||Central Nervous System Stimulation|
Medical Subject Heading (MeSH) Categories for amphetamine
|Country||Patent Number||Title||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2013003622||⤷ Try a Trial|
|European Patent Office||2726066||FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)||⤷ Try a Trial|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.